skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

29 Total results for product and free and sample content found

Generics Bulletin

Sun Finds US ‘Challenging’

Flags_USA_India

Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

Topic Deal trends

Generics Bulletin

Coherus Is Confident After US Ranibizumab Filing

Coherus_Is_Confident_After_US

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic Biosimilars Deal trends

Scrip

J.P. Morgan Conference Updates

JP_Morgan_Notebook_Day_1

Updates and coverage of the 2020 J.P. Morgan Healthcare Conference in San Francisco.

Scrip

Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law

Korea_2020_Outlook_Hopes_Of_Turnaround

After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.

Topic Clinical Trials Deal trends

Generics Bulletin

Biocon Biologics Gets True North Investment

Biocon_Biologics_Gets_True_North_Investment

Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

Topic Deal trends Strategy

Scrip

J.P. Morgan 2020: What To Watch For At The Industry's Biggest Meeting

JP_Morgan_2020_What_To_Watch

The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.

Scrip

Novartis Sees Reimbursement Advantage For PCSK9 Launch

Analysis

Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.

Topic Business Strategies Deal trends Reimbursement

Medtech Insight

Recipharm Boosts Inhalation And Injectables Manufacturing By Acquiring UK's Consort Medical

Article

Sweden's Recipharm has agreed to buy UK-based Consort Medical for £505m ($652m) to become a leading inhalation-device company and top five global CDMO.

Topic Deal trends

Generics Bulletin

Lupin Offloads Kyowa For $525m But Not Exiting Japan

Analysis

Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.

Topic Deal trends Strategy

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: